Voyager Therapeutics (VYGR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Voyager Therapeutics

NasdaqGS•Healthcare•Biotechnology

$3.51+0.13(0.04%)Market closed

Market Cap

$184.07M

P/S

5.3x

P/B

1.2x

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (5/25).

Profitability11/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredCash-backed earningsProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 13.1x5y range 2.8x – 50.6x

Currently above its 6-quarter median.

P/S · 5.3x5y range 1.5x – 9.4x

Currently above its 20-quarter median.

P/B · 1.2x5y range 0.7x – 4.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $184.07M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $34.46M
Q. Revenue: $3.17M
TTM EBITDA: $-113.37M
TTM Op. Income: $-117.19M
Q. Op. Income: $-26.39M
TTM Net Income: $-107.73M
Q. Net Income: $-24.47M
EPS: $-0.4
Shares Out.: $60.55M

$34.46M in TTM revenue declined 19.1% YoY, reaching $3.17M last quarter. TTM EBITDA of $-113.37M and TTM operating income of $-117.19M show growth is flowing through to the bottom line. However, net income is negative at $107.73M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -805.2%
Op. Margin: -833.9%
Net Margin: -773.2%

Op. margin of -833.9% is down 129.5% YoY — costs are rising relative to revenue. Net margin at -773.2% Over the past year, operating margin is down 18% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.3x
P/B Ratio: 1.2x

P/S of 5.3x and P/B of 1.2x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $197.75M
Cash: $35.77M
Long-Term Debt: N/A
Book Value: $154.38M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-25.84M
TTM Free Cash Flow: $-121.42M
FCF Margin: -352.4%
FCF / Net Income: 1.1

TTM FCF of $-121.42M on $-25.84M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.